Estimates of the duration of the early and late stage of gambiense sleeping sickness.

Hdl Handle:
http://hdl.handle.net/10144/29898
Title:
Estimates of the duration of the early and late stage of gambiense sleeping sickness.
Authors:
Checchi, F; Filipe, J A N; Haydon, D T; Chandramohan, D; Chappuis, F
Journal:
BMC Infectious Diseases
Abstract:
BACKGROUND: The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to predicting the impact of screening on transmission. Here, we outline a method to estimate these parameters. METHODS: We first model the duration of stage 1 through survival analysis of untreated serological suspects detected during Médecins Sans Frontières interventions in Uganda and Sudan. We then deduce the duration of stage 2 based on the stage 1 to stage 2 ratio observed during active case detection in villages within the same sites. RESULTS: Survival in stage 1 appears to decay exponentially (daily rate = 0.0019; mean stage 1 duration = 526 days [95%CI 357 to 833]), possibly explaining past reports of abnormally long duration. Assuming epidemiological equilibrium, we estimate a similar duration of stage 2 (500 days [95%CI 345 to 769]), for a total of nearly three years in the absence of treatment. CONCLUSION: Robust estimates of these basic epidemiological parameters are essential to formulating a quantitative understanding of sleeping sickness dynamics, and will facilitate the evaluation of different possible control strategies.
Affiliation:
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E7HT, UK. francesco.checchi@lshtm.ac.uk
Publisher:
BioMed Central
Issue Date:
8-Feb-2008
URI:
http://hdl.handle.net/10144/29898
DOI:
10.1186/1471-2334-8-16
PubMed ID:
18261232
Language:
en
ISSN:
1471-2334
Appears in Collections:
Trypanosomiasis/Sleeping Sickness

Full metadata record

DC FieldValue Language
dc.contributor.authorChecchi, F-
dc.contributor.authorFilipe, J A N-
dc.contributor.authorHaydon, D T-
dc.contributor.authorChandramohan, D-
dc.contributor.authorChappuis, F-
dc.date.accessioned2008-06-11T13:20:48Z-
dc.date.available2008-06-11T13:20:48Z-
dc.date.issued2008-02-08-
dc.identifier.citationEstimates of the duration of the early and late stage of gambiense sleeping sickness. 2008, 8:16 BMC Infect. Dis.en
dc.identifier.issn1471-2334-
dc.identifier.pmid18261232-
dc.identifier.doi10.1186/1471-2334-8-16-
dc.identifier.urihttp://hdl.handle.net/10144/29898-
dc.description.abstractBACKGROUND: The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to predicting the impact of screening on transmission. Here, we outline a method to estimate these parameters. METHODS: We first model the duration of stage 1 through survival analysis of untreated serological suspects detected during Médecins Sans Frontières interventions in Uganda and Sudan. We then deduce the duration of stage 2 based on the stage 1 to stage 2 ratio observed during active case detection in villages within the same sites. RESULTS: Survival in stage 1 appears to decay exponentially (daily rate = 0.0019; mean stage 1 duration = 526 days [95%CI 357 to 833]), possibly explaining past reports of abnormally long duration. Assuming epidemiological equilibrium, we estimate a similar duration of stage 2 (500 days [95%CI 345 to 769]), for a total of nearly three years in the absence of treatment. CONCLUSION: Robust estimates of these basic epidemiological parameters are essential to formulating a quantitative understanding of sleeping sickness dynamics, and will facilitate the evaluation of different possible control strategies.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rightsArchived with thanks to BMC Infectious Diseases by open access permission.en
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAnimalsen
dc.subject.meshChilden
dc.subject.meshDisease Progressionen
dc.subject.meshFemaleen
dc.subject.meshFollow-Up Studiesen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshPrevalenceen
dc.subject.meshSudanen
dc.subject.meshTrypanosoma brucei gambienseen
dc.subject.meshTrypanosomiasis, Africanen
dc.subject.meshUgandaen
dc.titleEstimates of the duration of the early and late stage of gambiense sleeping sickness.en
dc.contributor.departmentDepartment of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E7HT, UK. francesco.checchi@lshtm.ac.uken
dc.identifier.journalBMC Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.